Company: HCTI
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001213900-25-109581
Chunk: 38

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
20,674 
  
    Basic and diluted EPS - Stockholders 
     (2.23) 
     (224.10)
  
    Basic and diluted EPS - NCI 
    $(0.01) 
    $- 

  # Due to net loss position, basic and diluted weighted average shares outstanding are the same. 

8) Advertising and marketing 

Included within sales and marketing expenses are
the marketing and advertising expenses for the quarters ended September 30, 2025 and 2024, which were $649 and $78 respectively, and for
the nine months ended September 30, 2025 and 2024, were $943 and $545 respectively. The Company expenses advertising cost as and when
incurred.

30

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

9) Subsequent Events

    i.
    On August 28, 2025, the Company amended the acquisition agreement (see note 3.3a) to condition the issuance of the share consideration (as adjusted for the reverse stock split) upon shareholder approval. Accordingly, these shares were cancelled and have since been re-issued subsequent to the quarter end.

    ii. Subsequent to the quarter ended September 30, 2025, the Series A Warrants holders were provided with an option to exercise their warrants at a reduced price of $2 per warrant to convert into 1 common stock each and were given additional equivalent warrants at an exercise price of $3 per warrant. As a result of reducing the exercise price, 1,429,528 warrants were exercised, and the Company received gross proceeds of $2,859. Net proceeds to the Company were approximately $2,628, after deducting placement agent fees and other expenses payable by the Company. 

10) New Accounting Pronouncements

In March 2024, the FASB issued ASU No. 2024-01,
“Compensation—Stock Compensation (Topic 718): Scope Applications of Profits Interests and Similar Awards” (“ASU
2024-01”). ASU 2024-01 adds an example to Topic 718 which illustrates how to apply the scope guidance to determine whether profits
interests and similar awards should be accounted for as share-based payment arrangements under Topic 718 or under other U.S. GAAP. ASU
2024-01 is effective for annual periods beginning after